SAT-694 Association Between Engagement With The WeGoTogether Digital Self-support App And Weight Loss In A Real-world Setting

Abstract Disclosure: J. Toliver: Novo Nordisk. V. Divino: Novo Nordisk. C. Ng: Novo Nordisk. J. Wang: Novo Nordisk, Employee. Introduction: Obesity is a significant public health concern that contributes to several medical conditions and substantially increases healthcare costs and mortality. Semaglutide injection 2.4 mg (Wegovy®; hereafter referred to as semaglutide), a GLP-1 receptor agonist, received FDA approval in 6/2021 for chronic weight management in adults with overweight or obesity based on its efficacy and safety in the STEP series of phase 3, randomized, placebo-controlled trials. However, due to the relatively recent approval of semaglutide, there is limited real-world evidence on its long-term effectiveness. The current real-world study assessed weight loss at various time points in individuals treated with semaglutide who enrolled in the WeGoTogether digital patient support program. Methods: This retrospective cohort study included adults with overweight or obesity (BMI ≥25 kg/m2) who initiated semaglutide and enrolled in the WeGoTogether program during the study period (6/2021 to 4/2025). Participants had ≥2 weights any time after the index date (date of first semaglutide injection) and ≥1 weight at 6, 12, 18, or 24 months (±30 days) of follow-up. De-identified, self-reported data were analyzed from the WeGoTogether platform to understand patient characteristics at the index date and to assess changes in weight from the index date to 6, 12, 18, and 24 months of follow up. Weight outcomes were assessed among patients with an available weight within the ±30-day window for the indicated time point using the weight closest to the time point of interest. A subgroup analysis was conducted among patients with obesity (BMI ≥30 kg/m2). Results: A total of 8177 individuals were included in the study. At the index date, the mean (SD) patient age was 49.5 (9.9) years, weight was 106.4 (21.9) kg, and BMI was 38.4 (7.0) kg/m2; 83.6% were female. Among all patients, the mean (SD) percent weight loss from the index date was 13.4% (6.4) at 6 months (n = 6964), 17.6% (10.2) at 12 months (n = 2050), 20.3% (11.4) at 18 months (n = 491), and 20.4% (11.3) at 24 months (n = 325). The proportions of patients achieving ≥20% weight loss at 6, 12, 18, and 24 months were 13.1%, 43.3%, 52.7%, and 50.5%, respectively. In the subgroup with obesity (BMI ≥30 kg/m2), the mean (SD) percent weight loss from the index date was 13.4% (6.1) at 6 months (n = 6515), 18.0% (10.1) at 12 months (n = 1915), 21.2% (11.0) at 18 months (n = 454), and 21.2% (11.2) at 24 months (n = 296). The proportions of patients achieving ≥20% weight loss at 6, 12, 18, and 24 months were 12.9%, 44.3%, 55.7%, and 53.0%, respectively. Conclusions: Participants achieved substantial weight loss as reported in the WeGoTogether platform, including over long-term 18-month and 24-month follow-up periods, suggesting patients can achieve clinically meaningful weight loss in a real-world setting when participating in the WeGoTogether patient support program and receiving semaglutide. 1 Presentation: Saturday, July 12, 2025